CytomX Therapeutics, Inc.
CTMX · XNASCIK 1501989fmd_13SDJ99F6RFJ97SPV1868QE2NDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 15 | 72 | 60 | 27 | 68 | 37 | 53 | 101 | 138 | 76 |
| Research and development | 55 | 92 | 104 | 132 | 113 | 114 | 112 | 78 | 83 | 69 |
| Total operating expenses | 75 | 118 | 137 | 168 | 149 | 153 | 154 | 108 | 113 | 99 |
| Operating income | (60) | (46) | (78) | (141) | (81) | (116) | (101) | (6) | 25 | (22) |
| Interest expense | 2 | – | – | – | – | – | – | – | – | – |
| Interest and investment income | 1 | 3 | 8 | 8 | 2 | 0 | 2 | 10 | 7 | 5 |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (0) | (0) | 0 | (0) | (0) | 0 |
| Income before taxes | (59) | (44) | (70) | (133) | (79) | (116) | (99) | 3 | 32 | (17) |
| Income tax expense | (0) | (1) | 14 | (0) | (14) | 0 | 0 | 4 | 0 | 0 |
| Net income from continuing operations | (59) | (43) | (85) | (133) | (65) | (116) | (99) | (1) | 32 | (17) |
| Net income | (59) | (43) | (85) | (133) | (65) | (116) | (99) | (1) | 32 | (17) |
| Net income to common shareholders | (59) | (43) | – | – | – | – | – | – | 32 | (20) |